STEM:NASDAQ

StemCells Inc.

StemCells Inc. is engaged in the research and development of cell-based therapeutics. The company's proprietary HuCNS-SC cells (purified human neural stem cells) are currently in development as a potential treatment for a broad range of central nervous system disorders. The company is currently conducting phase 1/2 clinical trials in chronic spinal cord injury and dry age-related macular degeneration. StemCells Inc. is also pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine. The company markets stem cell research products, including media and reagents, under the SC Proven brand.

Expert Comments:

Prashanth Vempa, Alpha Deal Group (4/21/15)
"An inflection point is coming soon for StemCells Inc. Patient transplants are to gallop in 2015 and 2016; the company has an attractive valuation now, and additional clinical data over the coming years provide catalysts for future stock appreciation."

Henry McCusker, Regenerative Medicine Investors (4/16/15)
"StemCells Inc. has completed transplanting the six patients comprising the first cohort of its Phase 2 Pathway study. . .the first controlled study to use neural stem cells with the intent to demonstrate improvement in motor function following spinal cord injury. The company expects to release six-month interim data on the first cohort later this year."

"StemCells Inc. is doing pioneering work in the field of cervical spinal cord Injury and dry age-related macular degeneration (dry AMD). The Pathway Phase 2 study is the first clinical trial designed to evaluate both the safety and efficacy of transplanting human neural stem cells into patients with cervical spinal cord injury, including traumatic injuries to the cervical region of the spinal cord. . .the primary endpoints will assess changes in patient upper extremity strength as measured in the hands, arms and shoulders. . .the other very exciting program is in dry AMD. Positive Phase 1/2 data using the HuCNS-SC platform in dry AMD was presented at the 12th annual meeting of the International Society for Stem Cell Research. . .interim trial results show a 65% reduction in the rate of geographic atrophy (GA) in the study eye. . .as well as a 70% reduction in the rate of GA when compared to the control eye. . .interim results also indicate improvements in visual function, as measured by the ability to distinguish shades of light versus dark. . .contrast sensitivity was improved in four of the seven patients, and remained stable in the other three patients. . .the Phase 2 study should begin in early 2015." read more >

Jason Kolbert, Maxim Group (3/17/15)
"StemCells Inc. closed the year with $25M in cash. . .2015 represents a 'proof of concept' year for the company, and on good data, we should see a value inflection."

Jason Kolbert, Maxim Group (3/9/15)
"We see StemCells Inc. as the leader in the allogeneic, fetal-derived stem cell space; the company is working to move the field beyond the trophic effects of mesenchymal cells in central nervous system disorders. Two exciting indications are in Phase 2 proof-of-concept studies now: spinal cord paralysis and dry age-related macular degeneration."

Katherine Genis, Edison Investment Research (1/7/15)
"StemCells Inc.'s human neural stem cells (HuCNS-SC) are currently in clinical trials for dry age-related macular degeneration (AMD) and spinal cord injuries; a Phase 2 study program in both indications is underway, following early signs of efficacy in Phase 1/2 trials. Dry AMD could be a sizeable opportunity (we estimate $2B in peak sales) and represents the bulk of our overall valuation of the company at $189M, or $2.75/share."

More Comments

Experts Commenting on This Company


The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
StemCells Inc. Content